Generex Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
Go back to Generex Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer| Generex Biotechnology Corporation (AMEX: GNBT) | Delayed: 0.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.00 | 52 Week High | $0.01 | |||
| Open | $10.04 | 52 Week Low | $0.00 | |||
| Day High | $0.00 | P/E | 0.00 | |||
| Day Low | $0.00 | EPS | $-0.02 | |||
| Volume | 193 | |||||
